Double-blind placebo-controlled trial demonstrates sustained 24-hour nicotine delivery and reduced cigarette use in smokers, indicating transdermal patches support smoking cessation.
Key Points
To determine the pharmacokinetic profile of a transdermal nicotine patch and assess its clinical efficacy in a pilot smoking-cessation program.
Measured 24-hour plasma nicotine concentrations associated with transdermal nicotine patch application compared to cigarette smoking and other cessation devices.
Evaluated smoking cessation and reduction in a 6-week placebo-controlled double-blind pilot study.
Transdermal patch application maintained steady plasma nicotine concentrations comparable to smoking over a 24-hour duration, supporting a once-daily dosing regimen.
Treatment in the 6-week double-blind trial led to a statistically significant rate of smoking cessation or substantial reduction in smoking activity compared with placebo.